A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)
- Status
- COMPLETED
- Phase
- PHASE1
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
- Status
- COMPLETED
- Phase
- PHASE1
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Universal Prophylaxis Versus Pre-emptive Therapy With Posaconazole Post-Lung Transplant
- Status
- UNKNOWN
- Phase
- PHASE2
Contraception Initiation Feasibility in the Pediatric ED
- Status
- COMPLETED
- Phase
- NA
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
- Status
- COMPLETED
- Phase
- PHASE1
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)
- Status
- COMPLETED
- Phase
- PHASE1
Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
- Status
- COMPLETED
- Phase
- PHASE3
Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
- Status
- COMPLETED
- Phase
- PHASE3
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)
- Status
- COMPLETED
- Phase
- PHASE2